Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial

Wenjie Xiong; Rui Lyu; Ying Yu; Tingyu Wang; Yuting Yan; Yi Wang; Wei Liu; Gang An; Shuhui Deng; Yan Xu; Weiwei Sui; Wenyang Huang; Dehui Zou; Jianxiang Wang; Lugui Qiu; Shuhua Yi

doi:10.3324/haematol.2023.284588

Rituximab plus cyclophosphamide and dexamethasone versus bortezomib plus cyclophosphamide and dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia: a randomized controlled trial

Haematologica. 2024 May 1;109(5):1614-1618. doi: 10.3324/haematol.2023.284588.

Authors

Wenjie Xiong¹, Rui Lyu¹, Ying Yu¹, Tingyu Wang¹, Yuting Yan¹, Yi Wang¹, Wei Liu¹, Gang An¹, Shuhui Deng¹, Yan Xu¹, Weiwei Sui¹, Wenyang Huang¹, Dehui Zou¹, Jianxiang Wang¹, Lugui Qiu², Shuhua Yi³

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600.
² State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600. [email protected].
³ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China; Tianjin Institutes of Health Science, Tianjin 301600. [email protected].

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bortezomib* / administration & dosage
Bortezomib* / therapeutic use
Cyclophosphamide* / administration & dosage
Cyclophosphamide* / therapeutic use
Dexamethasone* / administration & dosage
Female
Humans
Male
Middle Aged
Rituximab* / administration & dosage
Rituximab* / therapeutic use
Treatment Outcome
Waldenstrom Macroglobulinemia* / diagnosis
Waldenstrom Macroglobulinemia* / drug therapy

Substances

Bortezomib
Cyclophosphamide
Dexamethasone
Rituximab

Associated data

ClinicalTrials.gov/NCT02844322

Grants and funding

Funding: This work was supported by grants from the National Nature Science Foundation of China (82370197, 81970187, 82170193, and 81920108006) and the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences (2022-I2M-1-022).